All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How effective is targeted therapy for Ph-like ALL?
Bookmark this article
During ESH 3rd How to Diagnose and Treat Acute Leukaemias the ALL Hub spoke with Emily Curran, University of Cincinnati, Cincinnati, US. We asked, How effective is targeted therapy for Ph-like ALL?
How effective is targeted therapy for Ph-like ALL?
Curran begins by outlining the Ph-like ALL subtype and current trial approaches, focusing on targets such as the ABL or JAK- targetable pathways. She discusses the results of some of this data in terms of clinical and pre-clinical models. Finally Curran discusses future studies, e.g. effectivity in less common Ph-like subtypes and the incorporation of novel immunotherapies like blinatumomab and Inotuzumab .
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox